Back to results
US 2017/0319694 A1Published application
Dihydroxyphenyl neurotransmitter compounds, compositions and methods
AssigneeAuspex Pharmaceuticals, Inc.
InventorsDavid S. Goldstein, Courtney Holmes, Rudolf-Giesbert Alken, Frank Schneider, Chengzhi Zhang
Life of this patent
Estimating the term…
Abstract
The present invention relates to new dihydoxyphenyl modulators of neurotransmitter levels, pharmaceutical compositions thereof, and methods of use thereof.
Claims26
A compound of structural Formula I:
- or a pharmaceutically acceptable salt thereof, wherein:
- R1-R2 are independently selected from the group consisting of hydrogen, deuterium, methyl, perdeuteromethyl, ethyl, perdeuteroethyl, propyl, perdeuteropropyl, butyl, perdeuterobutyl, C1-C6-alkyl, and C5-C6-cycloalkyl, wherein said C1-C6-alkyl and C5-C6-cycloalkyl may be optionally substituted with deuterium;
- R3-R8 are independently selected from the group consisting of hydrogen and deuterium;
- R9-R11 are independently selected from the group consisting of hydrogen, deuterium, methyl, perdeuteromethyl, ethyl, perdeuteroethyl, propyl, perdeuteropropyl, butyl, perdeuterobutyl, C1-C6-alkyl, and C5-C6-cycloalkyl, wherein said C1-C6-alkyl and C5-C6-cycloalkyl may be optionally substituted with deuterium;
- and
- at least one of R3-R6 and R8 is deuterium.
3 more elements
A pharmaceutical composition comprising a pharmaceutically acceptable carrier together with a compound of structural Formula I:
- or a pharmaceutically acceptable salt thereof, wherein:
- R1-R2 are independently selected from the group consisting of hydrogen, deuterium, methyl, perdeuteromethyl, ethyl, perdeuteroethyl, propyl, perdeuteropropyl, butyl, perdeuterobutyl, C1-C6-alkyl, and C5-C6-cycloalkyl, wherein said C1-C6-alkyl and C5-C6-cycloalkyl may be optionally substituted with deuterium;
- R3-R8 are independently selected from the group consisting of hydrogen and deuterium;
- R9-R11 are independently selected from the group consisting of hydrogen, deuterium, methyl, perdeuteromethyl, ethyl, perdeuteroethyl, propyl, perdeuteropropyl, butyl, perdeuterobutyl, C1-C6-alkyl, and C5-C6-cycloalkyl, wherein said C1-C6-alkyl and C5-C6-cycloalkyl may be optionally substituted with deuterium;
- and
- at least one of R3-R6 and R8 is deuterium.
3 more elements
A method of treatment of a neurotransmitter-mediated disorder comprising the administration of a therapeutically effective amount of a compound of structural Formula I:
- or a pharmaceutically acceptable salt thereof, wherein:
- R1-R2 are independently selected from the group consisting of hydrogen, deuterium, methyl, perdeuteromethyl, ethyl, perdeuteroethyl, propyl, perdeuteropropyl, butyl, perdeuterobutyl, C1-C6-alkyl, and C5-C6-cycloalkyl, wherein said C1-C6-alkyl and C5-C6-cycloalkyl may be optionally substituted with deuterium;
- R3-R8 are independently selected from the group consisting of hydrogen and deuterium;
- R9-R11 are independently selected from the group consisting of hydrogen, deuterium, methyl, perdeuteromethyl, ethyl, perdeuteroethyl, propyl, perdeuteropropyl, butyl, perdeuterobutyl, C1-C6-alkyl, and C5-C6-cycloalkyl, wherein said C1-C6-alkyl and C5-C6-cycloalkyl may be optionally substituted with deuterium;
- and
- at least one of R3-R6 and R8 is deuterium.
3 more elements
Dependencies are inferred from the claim text.